Skip to main content
. Author manuscript; available in PMC: 2017 Apr 15.
Published in final edited form as: Cancer Res. 2016 Feb 26;76(8):2432–2442. doi: 10.1158/0008-5472.CAN-15-2162

Figure 7. FACT is elevated in GBMs compared to normal brain tissues and its level correlates with survival and GSC gene signatures.

Figure 7

A, Normalized RNA expression levels in fragments per kilobase of transcript per million mapped reads (FPKM) of SSRP1 and SUPT16H were retrieved from GSE59612 (40) comparing their expression levels between contrast-enhancing glioma (n=39) versus non-neoplastic brain tissues (n=17) [unpaired Student’s t-test]. B, Kaplan-Meier survival plot of GBM patients with high (n=36) and low (n=133) expression of SSRP1 was downloaded from REMBRANDT (41). C, Expression levels (FPKM) of SOX2, OCT4, and NES were retrieved from RNA-seq data of contrast-enhancing glioma tissues (n=39) from GSE59612 and plotted against those of SSRP1 and SUPT16H [R2, regression coefficients; P values for linear regression]. D, Enrichment plots from GSEA for stem cell-related gene sets (false discovery rate, FDR ≤ 25%) in the primary single cell glioblastoma transcriptomes (GSE57872) expressing high SSRP1 (> 75 percentile, n=107) versus low SSRP1 (< 25 percentile, n=227).